Contrast medium-induced nephropathy.  
Aspects on incidence, consequences, risk factors and prevention

Gunnar Sterner¹ and Ulf Nyman²
(1) Department of Nephrology and Transplantation, Malmö University Hospital, Malmö, Sweden
(2) Department of Diagnostic Radiology, Lasarettet Trelleborg, Trelleborg, Sweden.

Abstract: Contrast media-induced nephropathy (CIN) is a well-known complication of radiological examinations employing iodine contrast media (I-CM). The rapid development and frequent use of coronary interventions and multi-channel detector computed tomography with concomitant administration of relatively large doses of I-CM has contributed to an increasing number of CIN cases during the last few years. Reduced renal function, especially when caused by diabetic nephropathy or renal arteriosclerosis, in combination with dehydration, congestive heart failure, hypotension, and administration of nephrotoxic drugs are risk factors for the development of CIN. When CM-based examinations cannot be replaced by other techniques in patients at risk of CIN, focus should be directed towards analysis of number and type of risk factors, adequate estimation of GFR, institution of proper preventive measures including hydration and post-procedural observation combined with surveillance of serum creatinine for 1-3 days. For the radiologist, there are several steps to consider in order to minimise the risk for CIN: use of “low-” or “iso-osmolar” I-CM and dosing the I-CM in relation to GFR and body weight being the most important as well as utilizing radiographic techniques to keep the I-CM dose in gram iodine as low as possible below the numerical value of estimated GFR. There is as yet no pharmacological prevention that has been proven to be effective.

Key Words: contrast media, nephropathy, creatinine, estimated GFR, radiology, acute renal failure

Introduction
Iodine contrast media (I-CM) are used in conjunction with x-ray procedures to enhance differences between normal body structures and pathological lesions. Side-effects of I-CM are common, one of the most severe being impairment of renal function. This complication has been known as a clinical entity for a long time. As early as the 1950s it was recognized that I-CM, especially after repeated administration, could be nephrotoxic [1]. The introduction of so called “low-osmolar” I-CM, shown to be less nephrotoxic than “high-osmolar” agents [2,3], during the 1970s was thought to reduce or eliminate this complication. This was, however, not found to be the case.

For many years contrast medium-induced nephropathy has been one of the most common causes of in-hospital acquired acute renal failure [4]. Only lately has the medical community come to an understanding of the risk factors involved in CIN and how this is best handled. Now in the early 21st century we have witnessed an increasing number of CIN cases in elderly patients being subjected to more and more advanced radiological examinations and percutaneous therapeutic interventions using I-CM. These procedures include the frequent use and rapid development of multi-channel detector computed tomography (MDCT) with concomitant administration of relatively large doses of I-CM [5]. Thus, there is an obvious risk that more patients will develop impaired renal function as the number of I-CM-enhanced radiological examinations will increase. In this situation it is important both for the physician and for the radiologist to consider what type of preventive measures should be taken. This overview will discuss incidence, consequences, and preventive measures to be considered when I-CM are administered, intravenously or intra-arterial.

Incidence
There are several definitions of CIN based on relative or absolute increase of serum creatinine. The most frequently used definition is a new onset or exacerbation of renal dysfunction after I-CM administration without other identifiable causes in combination with a rise in serum creatinine of at least 25% [6]. CIN occurs in less than 5% of a general population but in 10-30% of patients with renal insufficiency [3, 7-9]. In spite of the low risk for CIN in the general population, the vast numbers of examinations performed worldwide (about 80 million doses in 2003) indicate that CM complications will still affect a large number of patients. Patients exposed to CM are increasingly elderly with multiple co-morbidities that put them at increased risk. In patients with both renal insufficiency and diabetes, the incidence has been reported to be as high as 50% [10]. Up to 5% of patients with impaired renal function may develop CIN requiring dialysis [3,11]. Studies on computed tomography have reported a 4 to 21% incidence of CIN in patients with reduced renal function (a mean value of 12%) when data was pooled [12,13]. In a retrospective study of 703 consecutive patients with suspected acute pulmonary embolism subjected to acute CT examinations, we found a similar incidence of CIN [14]. However, none of the patients developed oliguria or needed dialysis. It was noted that generalised arteriosclerosis was commonly noted in the group that developed CIN.
Consequences
The consequences of CIN are prolonged hospital stay, increased non-renal morbidity, and increased cardiovascular risk and mortality [15-18]. McCullough et al [16] found that in-hospital mortality following coronary intervention was 7% in patients who develop CIN and 36% who develop CIN requiring dialysis. In patients not developing CIN under similar circumstances the figure was only 1%. Long-term survival was significantly less in those patients developing CIN than in those with stable renal function after I-CM administration [18]. The prognosis was especially grim in patients developing acute renal failure requiring hemodialysis with only 18% two-year survival [16].

A prospective, single center trial demonstrated that patients with no sustained elevated serum creatinine within the first few days after elective coronary angiography, but who developed this at 30-60 days post procedure, had a high mortality rate at two years [19]. Thus, I-CM administration could have more serious consequences than a transient fall in renal function.

Risk Factors
There are several established risk factors for CIN (table I), the most frequently cited being pre-existing renal impairment, especially if combined with diabetes mellitus [20-22]. Diabetes mellitus per se is not a risk factor in patients with normal renal function. Dehydration, congestive heart failure, hypotension, advanced age, and administration of nephrotoxic drugs are other common risk factors. The risk of CIN increases exponentially with the addition of multiple risk factors [21,23]. The combination of impaired renal function, reduced plasma volume, and congestive heart failure makes the patient especially vulnerable to CIN. This situation is common among many elderly patients. Special groups of interest are renal allograft recipients and those with multiple myeloma. Whereas patients with a kidney transplant are prone to develop CIN (reported incidence of 23%) [24], a review of 476 well dehydrated patients with myeloma, having undergone contrast media examination shows that only 0.6 – 1.25% demonstrated CIN. These figures are only slightly higher than the general population and indicate that the risk is due to level of renal function rather than myeloma per se [25].

After identifying risk factors, different scoring systems have been proposed to predict the risk of CIN. Some studies [21,26] have shown good correlation between risk score and CIN after coronary interventions. Nyman et al. [12] proposed to relate the planned I-CM dose in gram iodine numerically to the glomerular filtration rate (GFR), i.e. gram-iodine/GFR ratio, to predict the risk for CIN. The gram-iodine/GFR ratio is directly correlated to plasma under the concentration-time curve (AUC), a fundamental measure of systemic exposure of a drug excreted by glomerular filtration, and has been advocated for dose optimisation to avoid toxic effects [27,28].

Table 1

| Risk factors                          | Non-correctable factors | Correctable factors |
|--------------------------------------|-------------------------|---------------------|
| Pre-existing renal failure           | RF combined with diabetes mellitus | Hypotension |
| Congestive heart failure             | - Dehydration, Low plasma volume |
| Old age                              | - Nephrotoxic drugs |
| Renal transplantation                | - Volume and type of I-CM |
|                                      | - Repeated examinations |
|                                      | - Surgery early after administration of I-CM |

Prevention
Once CIN has developed, the only course is to treat the symptoms. Consequently any interventions must be preventive and focus on the patient at risk. These include adequate evaluation of renal function, identification of risk factors, institution of prophylactic measures, proper choice of I-CM, limiting the I-CM dose, or choosing an alternative diagnostic method.

Renal function
When evaluating risk for development of CIN, the essential question is whether renal function is normal or not. Traditionally serum creatinine has been used as an endogenous marker of GFR. It is well known, however, that serum creatinine has severe drawbacks caused by factors influencing both creatinine generation (muscle mass) and elimination (tubular secretion). Thus, serum creatinine will frequently overestimate renal function and is unreliable for proper evaluation of risk status when I-CM is to be given. It is most notable in patients over 70 years of age where GFR may be reduced below 50 ml/min in spite of a normal serum creatinine. This discrepancy was found in 50% of cases and was due to age-related decrease in muscular mass (creatinine generation) [29].

To improve prediction of renal function, GFR can be estimated with one of several published prediction equations based on anthropometric and/or demographic data apart from serum creatinine. The Cockcroft-Gault and the Modification of Diet in Renal Disease (MDRD)
Study formulas are presently the most frequently practised [30,31] However, a new creatinine based formula has recently been developed that, at least in the Scandinavian-Caucasian population, performed better than the Cockcroft-Gault and MDRD equation [32].

Lately reports have shown that GFR estimated from equations based on serum concentration of cystatin C are reliable values. Serum levels of cystatin C are not dependant on muscular mass and not secreted by renal tubules, the two main draw-backs of creatinine. GFR prediction equations based on cystatin C have been demonstrated to give similar or better results compared to the best known creatinine based equations [33].

Simple methods for rapid estimation of GFR with acceptable accuracy are thus available. Estimation of GFR via prediction equations is also recommended by several guidelines [34,35] and the risk of CIN is considered increased when estimated GFR falls below 60 ml/min. Thus, it is important to abandon serum creatinine as a sole marker of renal function and to focus on the available methods whereby GFR can be estimated. Also note that the patient’s absolute GFR in ml/min should be used when dosing drugs including I-CM [30]. Using relative GFR, i.e. normalisation to a certain patient size (most commonly 1.73 m² body surface area), will overestimate renal function in small individuals and underestimate it in large ones. It should, however, be noted that serum creatinine alone is a useful marker when following renal function after I-CM administration.

**Consider alternative diagnostic methods**

Alternative imaging techniques without I-CM should be considered in patients at risk of CIN. These include ultrasonography, CT without I-CM, magnetic resonance imaging (MRI) and scintigraphy. One should be liberal with performing CT without I-CM in risk patients before contemplating injection of I-CM since a non-enhanced CT is often satisfactory and can give adequate information for clinical decisions.

MRI may be performed with or without gadolinium (Gd) CM. The molecular doses of Gd-CM for MRI (0.1-0.3 mmol/kg) are generally much lower, roughly by a factor of ten, compared with the clinical doses of I-CM (30-90 gram iodine) used in radiographic examinations corresponding to 1-3 mmol non-ionic monomeric I-CM molecules per kg in an 80-kg person. The low doses of Gd-CM may explain their apparent non-nephrotoxic effects in certain studies [36]. However, recent studies also indicate a nephrotoxic potential of Gd-CM, especially in patients with severe renal impairment (GFR < 30 mL/min) [37-39], when injected in doses of 0.2-0.4 mmol/kg. Thus, the same preventive measures should be instituted in patients with renal impairment undergoing MRI with Gd-CM.

In addition, it has recently been reported that patients with renal failure (<15 mL/min) may develop nephrogenic systemic fibrosis (NSF)/nephrogenic fibrosing dermopathy (NFD), a delayed serious adverse reaction following examinations with Gd-CM [40,41]. The FDA advises careful examination of risks and benefits associated with using a gadolinium CM in patients with reduced GFR in light of recent reports of NSF/NFD following administration of these agents. They advise choosing an alternative imaging method and/or contrast agent whenever possible [42]. Furthermore it may be prudent to institute prompt dialysis in patients with GFR <15 ml/min if Gd-CM are clearly necessary.

**Adequate hydration**

Hydration is an important part of preventing CIN. It restores effective blood volume and prevents renal vasoconstriction and renal medullary hypoxia induced by contrast media [43]. Trivedi et al. [44] prospectively studied patients undergoing coronary angiography and found that the incidence of CIN was lower in patients who received IV 0.9% sodium chloride (saline) compared to those who received oral fluids. Approximately 100 mL or 1.5 mL/kg of fluid per hour, preferably saline, is recommended for 4-12 hours before to 12-24 hours after the examination [45]. However, volume and infusion rate must be balanced considering the patient’s fluid, cardiac, and renal status to provide for adequate diuresis without volume overload.

Intravenous infusion of sodium bicarbonate has been shown to be superior to saline for prevention of CIN in two prospective studies [46,47]. Although the mechanisms are unclear this interesting strategy may prove useful if confirmed in further studies.

**Pharmacological prevention**

Several trials have been performed to study the influence of different pharmacological agents to prevent CIN. Mannitol, furosemide, theophylline, dopamine, atrial natriuretic factor, and fenoldopam have been tested in clinical studies with no significant effect [34]. There are some data favouring the use of calcium channel blockers and theophylline for the prevention of CIN although their use is not widely accepted [48]. N-acetylcysteine (NAC) on the other hand is...
frequently being used to prevent or reduce the risk of CIN. A prospective, though low powered, study showed a lower risk of rise in serum creatinine after oral administration of NAC compared to a control group receiving only hydration in connection with computed tomography [49].

The mechanism for a possible protective effect of NAC is unclear. A cytoprotective effect due to scavenger of oxygen free radicals has been suggested as well as a vasodilatory effect. Recent meta-analyses, however, have not proved NAC to be advantageous compared to hydration alone [50,51]. There are also results indicating that NAC has specific effects on renal creatinine unrelated to renal function, which could explain the positive findings for the drug [52]. Thus, although cost is low and side-effects limited, NAC cannot be generally recommended for the prevention of CIN.

**Nephrotoxic substances**

Nephrotoxic substances may enhance the risk of CIN [53]. Non-steroidal anti-inflammatory drugs (NSAID) and cyclooxygenase inhibitors inhibit vasodilatory prostaglandins and could have negative effects on renal function especially in the presence of dehydration. Ideally administration of nephrotoxic drugs including NSAID, certain antibiotics (aminoglycosides), and cytostatics (cisplatin) should be stopped for at least 24 hours prior to a CM examination in patients at risk of CIN.

**Dialysis**

Contrast media, being water-soluble and not bound to protein, are promptly eliminated from the blood during hemodialysis [54]. The effect is even more pronounced when membranes with higher sieving coefficients or of other materials are used (high flux HD, hemofiltration). Several studies have investigated the role of post-contrast hemodialysis for prevention of CIN. The results published to date have been negative [54,55]. Marenzi et al. examined patients with p-creatinine above 176 umol/L undergoing coronary angiography and randomised to either “on-line” hemofiltration or traditional preventive measures. [56]. Patients treated with hemofiltration before and immediately after intravascular I-CM injection showed significantly lower incidence of CIN, defined as a 25% rise in serum creatinine, than control patients. It is unclear whether the effect was due to I-CM elimination or to a better control of plasma volume. As hemofiltration lowers serum creatinine, the evidence for a protective effect is not solid and further studies using proper GFR measurements are awaited.

**Type of iodine contrast medium**

It is now well recognized that ionic monomorphic “high-osmolar” I-CM (e.g. diatrizoate) developed 50 years ago are more nephrotoxic than today’s non-ionic monomeric (e.g. iohexol, iopromide, etc.) and ionic mono-acid dimeric (ioxaglate) “low-osmolar” I-CM or non-ionic dimeric “iso-osmolar” I-CM (iodixanol) [2,3]. Thus, low- or iso-osmolar CM should be used in patients at risk of CIN [35].

Two recent prospective randomised studies [57,58] and a meta-analysis [59] indicate that “iso-osmolar” I-CM is less nephrotoxic than “low-osmolar” I-CM in patients with diabetes mellitus and/or renal impairment. Speculations that the high viscosity of non-ionic dimers contributes to CIN have emerged from studies in rats [60] but could not be verified in a recent renal artery study of ischemic porcine kidneys [61]. Injections of a mean dose of about 70 mL iodixanol 320 mg I/mL directly into a renal artery occluded by a balloon caused no histomorphological changes and had no effect on GFR. These porcine results may be more relevant to humans than those studies done with rats, since anatomy and physiology of porcine kidneys are considered more like human kidneys than most other species.

**Gadolinium contrast media should not be used for x-ray examinations**

The apparent non-nephrotoxic effect of Gd-CM in MRI studies has encouraged many investigators to use Gd-CM as a substitute for I-CM in x-ray examinations including a variety of catheter-angiography procedures and CT [62,63]. However, the sole purpose for I-CM intended for radiographic examinations is to attenuate x-rays. In experimental porcine studies Gd-CM, especially of the “high-osmolar” type such as gadopentetate (1,96 Osm/kg H2O), has proven far more nephrotoxic than “low-” and “iso-osmolar” I-CM when injected in equal volumes and concentrations resulting in the same radio density. There is also a clinical study demonstrating a more pronounced nephrotoxic effect of Gd-CM than I-CM [64]. In fact plasma hyper-osmotic Gd-chelates imply a 75-year step-back regarding x-ray attenuation/osmotic ratio and should be contraindicated as a substitute for “low-“and “iso-osmolar” I-CM in azotemic patients undergoes CM-based x-ray examinations.

**Dosage of iodine contrast media**

The dose of I-CM should preferably be adjusted to the level of renal function and number and
types of examinations. Renal function should be expressed in GFR and not solely based on serum creatinine, which severely overestimates renal function in elderly patients. Preliminary investigations indicate that the gram iodine dose should not exceed the numerical value of estimated GFR. Ideally it should be as low as possible below that threshold value [12]. If multiple risk factors are present, the risk of CIN will rise exponentially [21,23,65,66]. Dosing per kg body weight at CT will markedly reduce the doses in patients with low BMI without losing diagnostic information compared with those patients who have higher BMI. The dose may be further reduced by employing 80 kV instead of the routine 120 kV at CT in patients with lower BMI [67].

In patients at risk of CIN, multiple I-CM-based examinations and/or major surgery should be delayed for at least three days combined with surveillance of serum creatinine. If there is elevated creatinine indicating CIN, a further delay of at least 7 days until creatinine has returned to baseline value is preferable.

Algorithm
An algorithm for avoiding nephropathy after administration of contrast media was recently suggested based on level of renal function [35]. If estimated GFR is < 60 mL/min and an I-CM examination is necessary, a number of measures should be considered including iv volume expansion, the use of “iso-" or “low-osmolar” I-CM, and a limited I-CM dose. For those patients who have GFR < 30 mL/min, in addition to employing the above measures, hospital admission, nephrology consultation and close follow-up is recommended. Dialysis support, should renal failure develop, must also be considered.

Conclusions
In patients at risk of CIN where CM-based examinations cannot be replaced by other techniques, the physician should focus on analysis of number and type of risk factors, adequate estimation of GFR, institution of adequate preventive measures, including hydration and post-procedural observation, combined with surveillance of serum creatinine for 1-3 days. For the radiologist, several things must be considered. In order to minimise the risk for CIN, use of “low- or “iso-osmolar” CM, dosing the CM in relation to estimated GFR and body weight (CT) are the most important, including utilizing radiographic technique to keep the CM dose in gram iodine as low as possible below the numerical value of estimated GFR (see authors’ guidelines). There is as yet no pharmacological preventive treatment that has been proven effective but with careful pre-examination evaluation, the risks can be minimised.

Author’s Guidelines
1- Serum creatinine requirements for predicting GFR with equations: Any patient with suspected or known renal disease/-surgery/-impairment, diabetes mellitus, congestive heart failure, age ≥ 70 years or any other obvious risk factor.
1. Alwall N, Johnsson S, Tomberg A, Werklö L. Acute renal failure following angiography. Acta Chir Scand 1955; 109:11-19.
2. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171-178.
3. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. The iohexol Cooperative Study. Kidney Int 1995; 47:254-261.
4. Thomsen HS. Nephrotoxicity. Thomsen HS, Muller RN, Mattrey RF editors. Trends in contrast media. Springer Berlin, Heidelberg, New York 1999: 103-116.

5. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int 2006; 69:53-57.

6. Morcos SK. Prevention of contrast media nephrotoxicity – the story so far. Clin Radiol 2004; 59:381-389.

7. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, MacManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Eng J Med 1989; 320:143-149.

8. Morcos SK, Thomsen HS, Webb JAV. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 1999; 9:1602-1613.

9. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004; 183:1673-1689.

10. Manses CL, Sprafka JM, Strongy JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615-620.

11. Davidson CJ, Hilaiky M, Morris KG, Pieper K, Skelton TN, Schwab SJ, Bashore TM. Cardiovascular and renal toxicity of a non-ionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Int Med 1989; 110:119-124.

12. Nyman U, Almén T, Aspelin P, Hellström M, Kristiansson M, Sterner G. Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. Acta Radiol 2005; 46:830-842.

13. Becker CR, Reiser MF. Use of iso-osmolar non-ionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest Radiol 2005; 40:672-675.

14. Haglund M, Hesseistrand R, Nyman U, Sterner G. Contrast-induced nephropathy after computer tomography, Hydration and adapted contrast media dosage for the best prophylaxis. Lakartidningen 2005; 102:2864-2870.

15. Levy EM, Viscoti CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275:1489-1494.

16. McCullough PA, Wolyrn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375.

17. Dangas G, Iakovou J, Nikolovsky E, Aymong ED, Mintz GS, Kipscheidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R, Sterner G. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95:13-19.

18. Rihal CS, Teztor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Gurratt KN, Holmes DR. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264.

19. Reinecke H, Folkner M, Wellman J, Becke B, Fleiter J, Heilmeyer C, Breithardt G, Hense HW, Schaefer RM. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast nephropathy. The Dialysis-versus- Diuresis (DViD) Trial. Clin Res Cardiol 2007; 96(3):130-139.

20. Asif A, Preston RA, Roth D. Radio-contrast-induced nephropathy. Am J Ther 2003; 10:137-147.

21. Mehran R, Aymong ED, Nikolovsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Loco MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol 2004; 44:1393-1399.

22. Nikolovsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 69;(Suppl 100):S11-S15.

23. Freeman RV, O’Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, DeFranco AC, Eagle KA, McGinnity JG, Patel K, Maxwell-Eward A, Bondle D, Moscucci M. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002: 90:1068-1073.

24. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephropathy in renal allograft recipients. Clin Nephrol 2000; 54:11-14.

25. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183:519-521.

26. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O’Neill WW. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93:1515-1519.

27. Chen ML, Lesko L, Williams RL. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet 2001; 40:565-572.

28. Sherwin PF, Cambron R, Johnson JA, Pierro JA. Contrast dose-to-creatinine clearance ratio as a potential indicator of risk for radio-contrast-induced nephropathy. Invest Radiol 2005; 40:598-603.

29. Duncan L, Heathcote C, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing. Nephrol Dial Transplant 2001; 16:1042-1046.

30. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function – measured and estimated glomerular filtration rate. N Eng J Med 2006; 354:2473-2483.

31. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Int Med 2006; 145:247-254.

32. Björk J, Bäck S-E, Sterner G, Carlson J, Lindström V, Bakhous O, Simonsson P, Grubb A, Nyman U. Prediction of relative GFR in adults. New improved equations based on Swedish Caucasians and standardized plasma-creatinine assays. Accepted for pub in Scand J Clin Lab Invest.

33. Grubb A, Nyman U, Björk J, Lindström V, Rippe B, Sterner G, Christensson A. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Couranah-Barratt prediction equation for children. Clin Chem 2005; 51:1420-1431.

34. KDQCI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1):S1-524.

35. Contrast-induced nephropathy: Clinical insights and practical guidance. A report from the CIN consensus working panel. Am J Cardiol 2006; 98(Suppl):1K-77K.

36. Prince MR, Arnoldus C, Frisolli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996; 6:162-166.

37. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003; 38:313-318.

38. Ergün I, Keven K, Uruc I, Ekmecki Y, Canbakan B, Erden I, Karatan O. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006; 21:697-700.

39. Briquori C, Colombo A, Airoldi F, Melzi G, Michele C, Carlino M, Montorfano M, Chieffo A, Bellanca R, Ricciardelli B. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 2006; 67:175-180.

40. Marcinkmann P, Skov L, Rossen K, Dupont A, Dammholt MB, Heaf JG, Thomsen HS. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Am J Soc Nephrol 2006; 17:2359-62.
41. Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermalopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 2006; 21:1104-1108.

42. U.S. Food and Drug Administration. Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging Scans (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance). Accessed February 9, 2007 http://www.fda.gov/cder/drug/InfoSheets /HCP/gcca_200612HCP.htm.

43. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int 2006; 69:S16-S19.

44. Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephropathy. Nephron Clin Pract 2003; 93:c29-c34.

45. Thomsen H. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR 2003; 181:1463-1471.

46. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bensin RM, Van Moore A, Simonton CA, Rittase RA, Norton HJ. Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328-2334.

47. Briguori C, Airoldi F, DÁndrea D, Bonizzone E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrafe J, Ricciardelli B, Colombo A. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211-1217.

48. Stacul F, Adam A, Becker CR; Davidson C, Lameire N, McCullough PA, Tumlin J. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98 (suppl): 59K-77K.

49. Tepel M, Van der Giet M, Schwarzfeld C, Lauffer U, Lierman D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Eng J Med 2000; 343:180-184.

50. Naillamothe BK, Shojania KG, Saint S, Hofer TP, Hummes HD, Moscuccio M, Bates ER. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analyses. Am J Med 2004; 117:938-947.

51. Biondi-Zoccai GGL, LotrionteM, Abbate A, Testa L,Remigi E, Buzzotta F, Valgimigli M, Romagnoli E, Crea F, Ageno P. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006; 332:1-8.

52. Hoffmann U, Fischeder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407-410.

53. Eyer C. Concomitant drugs with exposure to contrast media. Kidney Int 2006; 69:S20-S24.

54. Stener G, Frennbry B, Kurkus J, Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol 2000; 34:323-326.

55. Deray G. Dialysis and iodinated contrast media. N Engl J Med 1993; 329:1333-1340.

56. Aspelin P, Aubry B, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499.

57. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006; 48:924-30.

58. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of iso-osmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2008; 48:692-699.

59. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68:14-22.

60. Elmstahl B (2006) Are gadolinium contrast media really less nephrotoxic than iodine agents in radiographic examinations? A comparison in relation to their ability to attenuate x-rays in a pig model. In: Lund University Faculty of Medicine. Doctoral Dissertation Series 2006; 9, Lund, Sweden.

61. Spinoso DJ, Kaufmann JA, Hartwell GD. Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. Radiology 2002; 223:319-325; discussion 326-317.

62. Remy-Jardin M, Bahepar J, Laffitte JJ et al. Multi-detector row CT angiography of pulmonary circulation with gadolinium-based contrast agents: prospective evaluation in 60 patients. Radiology 2006; 238:1022-1035.

63. Briguori C, Colombo A, Airoldi F, Melzi G, Michev I, Carlino M, Montorfano M, Chieffo A, Bellancia R, Ricciardelli B, Gadolinium-based contrast agents and nephropathy in patients undergoing coronary artery procedures. Cath Cardiovasc Interventions 2006; 67:175-180.

64. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med. 1990; 150:1237-1242.

65. Marenzi G, Lauri G, Assanelli E, Campodonicio J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44:1780-5.

66. Holmquist F, Nyman U. Eighty-peak kilovoltage 16-channel multidetector computed tomography and reduced contrast-medium doses tailored to body weight to diagnose pulmonary embolism in azotemic patients. Eur Radiol 2006; 16:1165-1176.

67. Stener G, Nyman U, Valdes T. Low risk of contrast medium induced nephropathy with modern angiographic technique. J Int Med 2001;250:429-434.

68. Stner G, Nyman U, Valdes T. Low risk of contrast medium induced nephropathy with modern angiographic technique. J Int Med 2001;250:429-434.

69. Farinas PL. A new technique for the arteriographic examination of the abdominal aorta and its branches. AJR 1941; 46:641-645.

70. Awai K, Hori S. Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT. Eur Radiol. 2003; 13:2155-2160.